Chakalova G, Dimitrova N, Gavrilov I, Valerianova Z
Department of Gynecologic Oncology, National Oncology Hospital, Sofia, Bulgaria.
J BUON. 2013 Oct-Dec;18(4):1038-44.
In Bulgaria, there are over 3700 cases diagnosed with breast cancer annually and over 3300 with gynecological cancers. The purpose of this study was to estimate the burden of breast and gynecological cancers in Bulgaria, analyzing trends of incidence, mortality and survival for the past two decades.
Data from the Bulgarian National Cancer Registry for women diagnosed with cancer of breast (C50, ICD10), cervix uteri (C53), corpus uteri (C54) and ovary (C56) during 1993 - 2009 were analyzed. Age-standardized incidence and mortality rates (ASR) per 100,000 persons were calculated using the world standard population. Average annual percent changes (AAPC) for 1993-2009 were estimated by Joinpoint regression. The observed survival was analyzed with the Life Table method for two periods: 1993-1997 and 2005-2009.
Incidence rates of the most frequent cancers among Bulgarian women are increasing - from 1.7% to 2.6% annually. Mortality rates are decreasing significantly for breast (-0.8% annually) and increasing for corpus uteri cancers (4.9% annually). Survival for all sites increased from 3 to 8% over the study period. We observed greater proportion of cases diagnosed in stage I in 2009 than in 1993, for the 4 sites.
These results indicate some differences in trends in incidence and mortality of the reviewed sites compared with other European countries, highlighting the need for more strict adherence to integrated treatment standards and the necessity of introduction of population screening programs.
在保加利亚,每年有超过3700例乳腺癌病例被诊断出来,超过3300例妇科癌症病例。本研究的目的是评估保加利亚乳腺癌和妇科癌症的负担,分析过去二十年的发病率、死亡率和生存率趋势。
分析了保加利亚国家癌症登记处1993 - 2009年期间诊断为乳腺癌(C50,ICD10)、子宫颈癌(C53)、子宫体癌(C54)和卵巢癌(C56)的女性数据。使用世界标准人口计算每10万人的年龄标准化发病率和死亡率(ASR)。通过Joinpoint回归估计1993 - 2009年的年均变化百分比(AAPC)。采用生命表法分析1993 - 1997年和2005 - 2009年两个时期的观察生存率。
保加利亚女性中最常见癌症的发病率正在上升——每年从1.7%升至2.6%。乳腺癌死亡率显著下降(每年-0.8%),子宫体癌死亡率上升(每年4.9%)。在研究期间,所有部位的生存率从3%提高到了8%。我们观察到,2009年四个部位I期诊断病例的比例高于1993年。
这些结果表明,与其他欧洲国家相比,所审查部位的发病率和死亡率趋势存在一些差异,突出了更严格遵守综合治疗标准的必要性以及引入人群筛查计划的必要性。